Hyperuricemia as a Risk Factors of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome: a Retrospective Cohort Study
ABSTRACT: to investigate the
MACE-free survivals difference between hyperuricemic and normouricemic patients
and to determine its role as risk factor for MACE occurrence in hospitalized
acute coronary syndrome patients. Methods: retrospective cohort study with
survival analysis approach was conducted in 251 patients with acute coronary
syndrome who were treated in ICCU Cipto Mangunkusumo Hospital during period
from January 2009 to December 2011. Clinical data, laboratory results,
electrocardiography result, echocardiography result, and coronary angiography
were collected. Patients were observed and followed on major adverse cardiac
event during 7 days of hospitalization in ICCU. Major adverse Cardiac Event is
an event as a complication occur after acute coronary syndrome such as
cardiogenic syock, acute heart failure, stoke, reinfarct during early ward
treatment, sudden cardiac death, repeat PCI during ward ulang and perform
coronary artery bypass graft (CABG) surgery. Difference in survival is shown in
Kaplan-meier curve and difference in survival between groups were tested with
Log-rank test, and multivariate analysis with Cox proportional hazard
regression to calculate adjusted HR on major adverse cardiac event with confounding
variables as covariates. Results: there was a signifcant difference in survival
between hyperuricemia group and non-hyperuricemia group (Log-rank test (p<0.001))
with crude HR 2.7 (CI 95% 1.6–4) and adjusted HR 2.67 (CI 95% 1.6-4.3).There
was signifcant difference in survival between hyperuricemia group (mean
survival 6.05 days with SE 0.2 (CI 95% 5.6-6.4) and non-hyperuricemia group
(mean survival 7.33 days with SE 0.1 (CI 95% 7.0-7.6). Conclusion: survival of
patients suffering from ACS with hyperuricemia is worse compared to those
without hyperuricemia during ICCU hospitalization.
Author: Birry Karim, Sally A.
Nasution, Ika P. Wijaya, Kuntjoro Harimurti
Journal Code: jpkedokterangg150234
